No : 19287-45-7) at low concentrations, male ICR mice were exposed to di borane for 1, 2, 4 or 8h at concentrations of 1 or 5 ppm (phase I study), and for 6h/day, 5 days/wk, over 2 or 4wk at concentrations of 0.2 or 0.7ppm (phase II study).
Ten mice in each group were exposed to 1 or 5 ppm of diborane for 1, 2, 4 or 8h (phase I study) and to 0.1 or 1ppm of diborane for 2 or 4 wk (phase II study). Control mice were exposed to filtered room air in the same way as exposed groups.
The behavior and external appearance of mice were checked everyday. In the phase II study, body weight was measured every morning before expo sure from Monday through Saturday.
The mice were anaesthetized with sodium pento barbiturate and sacrificed by exsanguination from the inferior vena cava 3 days after exposure in the phase I study, and on the day after the last expo sure in the phase II study. The organs were ex amined grossly and the nasal mucosa, respiratory tract and lung were examined histopathologically, since histopathological changes were observed only in these organs in experiments with higher exposure1). The organs were placed in 10% buffer ed neutral formalin solution. The skull was decalci fied in 10% formic acid solution for histopatholog ical examination of the nasal mucosa. Other tissues were embedded in paraffin, sectioned and stained with hematoxylin and eosin using standard histolog ical procedures.
The hematological and serum biochemical items examined were erythrocyte counts (RBC), total and differential leucocyte counts (WBC), hemoglobin concentration (Hb), hematocrit (Ht), elastase-1 (BL-1), lipid peroxidase (LPO), lactate dehydroge nase (LDH), alanine aminotransferase (ALT), as partate aminotransferase (AST), alkaline phospha tase (ALP), blood urea nitrogen (BUN), sodium (Na), potassium (K) and chlorine (CI).
Results
In the phase I study, the mean diborane concen trations were 0.94ppm or 4.88ppm in the 1-h exposure study, 0.91ppm or 4.92ppm in the 2-h exposure study, 0.94ppm or 4.94ppm in the 4-h exposure study and 0.95ppm or 4.91ppm in the 8-h exposure study, and in the phase II study, the mean diborane concentrations were 0.17ppm or 0.69ppm in the 2-wk exposure study and 0.17ppm or 0.62ppm in the 4-wk exposure study (Table 1) .
There were no significant differences in behavior or external appearance between control and exposed mice in either of the phase studies.
In the phase I study, there was no significant diff erence in body weight between control and exposed mice after diborane exposure. In the phase II study, no dose-related difference was observed in weekly gain of body weight. In the phase I study, lung weight was significant ly increased in mice exposed to 5ppm for 8h and significantly decreased in mice exposed to 1ppm for 1, 4 and 8h (Table 2 ). In the phase II study, lung weight was significantly greater in mice exposed to 0.7ppm for 2wk (Table 2 ).
In the phase I study, diffuse panbronchiolitis-like obstructive change was observed in mice exposed to 5ppm of diborane (Table 3) , and this response was dose and exposure length-related. In the phase II study, we did not find peribronchiolar lymphoid hyperplasia with infiltration of macrophage into al veoli and the bronchiolar area; as reported in our previous study on subacute higher exposure1). However slight infiltration of polymorphous neutro phil, mainly in the peribronchiolar region, was ob served in mice exposed to 0.2ppm or 0.7ppm of diborane for 2 or 4wk (Table 3 ). This response in dicated dose-response relationship.
In the phase I and II studies, differential leuco cyte counts in exposed mice showed sporadically significant increases or decreases compared with control groups, but no clear dose-related trend was observed (Tables 4, 5 ). The other hematological and biochemical examinations did not show dose related differences. Discussion Krackow2) reported that rats exposed to 5.3ppm of diborane for 2 to 3wk showed pulmonary damage. In their 4-wk inhalation study at an expo sure level of 2ppm (0.9-3.5ppm), infiltration of round cells was observed in the tracheal mucosa, but not in the alveoli and bronchiolar area. Kunkel et al. al.3) reported that acute exposure caused pulmo nary edema in experimental animals. In our study, histopathological changes were observed in the alv eoli or bronchiolar area in both acute (5ppm of diborane) subacute (0.2 or 7ppm of diborane) ex posure studies ( Table 3 ). Considering that the half life of diborane is 0.8-1.5h in a condition of satu rated humidity at room temperature4), diborane rea ches the alveolar area and a small amount of it may dissolve. In alveoli and the bronchiolar area, dibor ane and disintegrated compounds may show irritat ing toxicity with thermal reaction of hydrolysis. Comstock et al.5) reported that 5 of 10 rats exposed to 1-2ppm of diborane died at 60 exposures (6h/ exposure), and 5 of 10 rats exposed to 5.3ppm of diborane died at 113 exposures (6h/exposure). However, no pathological change was observed in the lung. Neither study conducted by Krackow2) nor the present study show such a low lethal con centration of diborane. Possible reasons for the dis crepancy may be differences in the purity of di borane and the accuracy of diborane measurement.
In the phase I study, a dose-response relationship was observed in the histopathological findings (Table 3) . Histopathologically, diffuse panbron chiolitis-like obstructive change in acute exposure seemed to resemble the finding of lung exposed to other gasses like nitrogen dioxide which affect the distal portion of the airways. In the phase II study, although slight infiltration of polymorphous neutro phil, mainly in the peribronchiolar region, indicated a dose-response relationship, interpretation of this pathological change is unclear. Further studies, such as bronchoalveolar lavage fluid examination, are necessary to get more detailed information on subacute lung toxicity.
In conclusion, no-observed-effect level diborane toxicity in acute exposure on the lung was 1ppm, while in subacute exposure 0.2ppm of diborane in halation for 2 or 4wk seems to be unsafe. 
